Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lupin In Tailspin After Two-In-One FDA Warning Letter

Executive Summary

After a weak second quarter, Lupin had a nasty surprise with the FDA issuing a combined warning letter for two of its Indian manufacturing sites. The FDA action is expected to setback US product approvals, though Lupin maintained that its “structural story of growth” remained intact.

You may also be interested in...



Lupin Slumps To Q4 Loss Amid US Opioid Action But Build Up In Inhalation, Biosimilars

Lupin ended the fourth quarter in the red hit by an impairment provision related to the "underperforming" assets of its Gavis acquisition but the firm's US inhalation pipeline appears to have made some progress, including a filing for tiotropium dry powder inhaler (DPI). Early stage biosimilars under development include, among others, versions of Neulasta and Xgeva/Prolia.

Lupin Upbeat On Biosimilar Etanercept After Q3 Profit Plunge

After a bruising financial third quarter in which net quarterly profit plunged 65%, Lupin reported “a successful outcome” for clinical trials of its rheumatoid arthritis drug etanercept, its first biosimilar product for the global market.

Lupin Upbeat On Biosimilar Etanercept After Q3 Profit Plunge

After a bruising financial third quarter in which net quarterly profit plunged 65%, Lupin reported “a successful outcome” for clinical trials of its rheumatoid arthritis drug etanercept, its first biosimilar product for the global market.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1131516

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel